Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockSermorelin / Ipamorelin
Third-Party TestedPurity Standards
Total
$59.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Peptide blend
Sermorelin (GHRH(1-29) amide)
Molecular formula
C149H246N44O42S
Molecular weight
3357.9 g/mol
CAS number
86168-78-7
Sequence
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Ipamorelin
Molecular formula
C38H49N9O5
Molecular weight
711.9 g/mol
CAS number
170851-70-4
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Mechanism & Target Class
Mechanism & Target Class
Combines two synthetic peptides with distinct molecular structures. The first component is a 29-residue C-terminally amidated fragment analog corresponding to the N-terminal GRF(1-29) sequence; in structural studies it engages a class B1 (secretin-family) G-protein-coupled receptor, with cryo-EM resolving the peptide contacts across the receptor transmembrane bundle, extracellular loops, and extracellular domain. The second component is a 5-residue pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) incorporating non-standard residues — an N-terminal Aib and D-amino-acid substitutions — that confer conformational constraint and protease resistance; in structural studies it occupies the ligand-binding pocket of a class A G-protein-coupled receptor. Both components have been resolved in receptor–ligand complexes at near-atomic resolution, supplying molecular-level reference structures for each peptide's GPCR engagement.
Storage & Handling
Storage & Handling
Lyophilized
−20°C (−80°C long-term)
powder protected from moisture and light.
Aliquot to avoid freeze-thaw cycles; protect from light and moisture.
References
References
Reviews
- 1
Walker RF. (2006). Clin Interv Aging
- 2
Holst B, Schwartz TW. (2004). Trends Pharmacol Sci
Reviews
- 3
Laviano A, Molfino A, Rianda S, Rossi Fanelli F. (2012). Curr Pharm Des
- 4
Cong Z, Liang YL, Zhou Q, et al. (2022). Trends Pharmacol Sci
- 5
Halmos G, Szabo Z, Dobos N, et al. (2025). Rev Endocr Metab Disord
Clinical
- 6
Beck DE, Sweeney WB, McCarter MD, et al. (2014). Int J Colorectal Dis
- 7
Pastuszak AW, Sigalos JT, Allison A, et al. (2017). Am J Mens Health
- 8
Veldhuis JD, Bowers CY. (2009). Am J Physiol Endocrinol Metab
- 9
Hindmarsh PC, Brain CE, Robinson IC, et al. (1991). Clin Endocrinol (Oxf)
- 10
Achermann JC, Hindmarsh PC, Robinson IC, et al. (1999). Clin Endocrinol (Oxf)
- 11
Corpas E, Harman SM, Piñeyro MA, et al. (1992). J Clin Endocrinol Metab
- 12
Hataya Y, Akamizu T, Takaya K, et al. (2001). J Clin Endocrinol Metab
- 13
Brain CE, Hindmarsh PC, Brook CG. (1990). Clin Endocrinol (Oxf)
- 14
Gobburu JV, Agersø H, Jusko WJ, Ynddal L. (1999). Pharm Res
Primary research
- 15
Zhou F, Zhang H, Cong Z, et al. (2020). Nat Commun
- 16
Yang H, Liu F, Chen W, et al. (2021). Nat Commun
- 17
Raun K, Hansen BS, Johansen NL, et al. (1998). Eur J Endocrinol
- 18
Wilton P, Chardet Y, Danielson K, et al. (1993). Acta Paediatr Suppl
- 19
Johansen PB, Nowak J, Skjaerbaek C, et al. (1999). Growth Horm IGF Res
- 20
Johansen PB, Hansen KT, Andersen JV, Johansen NL. (1998). Xenobiotica
- 21
Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. (2002). Histol Histopathol
- 22
Andersen NB, Malmlöf K, Johansen PB, et al. (2001). Growth Horm IGF Res
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
